Baarayaasha goobta Memorial Sloan Kettering Cancer Center iyo Massachusetts Institute of Technology waxay sameeyeen hannaan cusub oo saddex-tallaabo ah oo isticmaala dawooyinka nukliyeerka si loo beegsado loogana takhaluso kansarka mindhicirka. Cilmi baarayaashu waxay heleen 100% heerka bogsashada ee qaabka jiirka wax saameyn ah sun ahna kuma lahan daaweynta. Warbixinta cilmibaarista waxaa lagu daabacay joornaalka Nofeembar ee Daawada Nukliyeerka.
Ilaa hadda, radioimmunotherapy (therapy therapy) iyadoo la adeegsanayo anti-beegsada radionuclides si loo daaweeyo burooyinka adag ayaa leh waxtar yar. “Tani waa daraasad ugub ah. Waa shucaac labaad oo aan sun ahayn oo unugyada caadiga ah ee jidhka bini'aadamka ee daaweynta qiyaasta burooyinka. ” Steven m. Larson iyo Dr. Sarah Cheal ayaa sharraxay, “Guusha tusaalaha burooyinka jiirku waxay ka imaneysaa kooxda Tayada gaarka ah ee reagent-yada soo baxay, dhanka kale, waxay ka imaaneysaa hababka tababarka ee la yareeyay, oo ay ku jirto habka baaritaanka daaweynta ee si fudud loogu wareejin karo bukaanka. “Habkani wuxuu adeegsadaa hal dawo oo lagu baaro laguna daweeyo cudurada. Daawada ayaa marka hore heleysa unugyada kansarka ka dibna way baabi'ineysaa si unugyada caafimaadka qaba aan loo waxyeeleyn. Sidan oo kale, dhibaatooyinka soo raaca waa la yareeyaa tayada bukaankana waa loo hagaajiyaa.
Daraasaddan, glycoprotein A33 (GPA33) ayaa loo isticmaalay in lagu aqoonsado A33 buro antigen. DOTA-pre-targeted radioimmunotherapy (PRIT) ayaa lagu tijaabiyay qaabka jiirka. Jiirarka tijaabada ah ee si aan kala sooc lahayn loo doortay, sawirka SPECT/CT ayaa loo isticmaalay si loola socdo jawaabta daawaynta, waxaana la xisaabiyay qiyaasta shucaaca ee burada. Jiirarka la tijaabiyay ayaa si fiican ugu jawaabay. Mid ka mid ah jiirarka la qiimeeyay ma muujin calaamadaha kansarka ee mikroskoob-ka, mana jirto waxyeello shucaac ah oo lagu arkay xubnaha muhiimka ah oo ay ku jiraan dhuuxa iyo kelyaha.
Qiyaasta daaweynta 100% ee qaabka jiirka ayaa ah soo dhaweyn la soo dhoweynayo, oo muujineysa in anti-GPA33-DOTA-PRIT ay noqon doonto nidaam daaweyn radioimmunotherapy wax ku ool ah oo loogu talagalay GPA33-kansarka mindhicirka wanaagsan.
Sida laga soo xigtay CDC, kansarka malawadka waa kansarka saddexaad ee ugu badan ee saameeya ragga iyo dumarka. Dalka Mareykanka, waxaa jira ku dhowaad 140,000 oo xaaladood oo cusub sanad walba iyo 50,000 oo dhimasho ah.
Larson iyo Cheal waxay aaminsan yihiin in haddii guul laga gaaro bukaan-socodka, in daaweyntan nukliyeerka ah loo gudbin karo kansarrada kale. Nidaamka waxaa loogu talagalay inuu yahay nidaam "fura iyo ciyaar" ah oo aqbali kara noocyo kala duwan oo kahortaga jirka antigens burooyinka bini'aadamka, mabda 'ahaanna waa mid lagu dabaqi karo dhammaan burooyinka adag iyo dareeraha ee jirka aadanaha. Waxay intaas ku dareen "cilmiga kansarka, gaar ahaan burooyinka kala duwan ee adag oo ay ka mid yihiin xiidanka, naaska, xammeetida, melanoma, sambabka iyo hunguriga, waxaa jira baahi weyn oo loo qabo in lagu daaweeyo cudurrada horumarsan."
